Gain Therapeutics Inc. (GANX)
$1.82
$-0.01
(-0.27%)
As on 04-Sep-2026 13:32EDT
Market cap
$77 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
7.2
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-2.7 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-1.5
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-0.5
-
Face value
--
-
Shares outstanding
43,643,619
6 Years Aggregate
CFO
$-51.78 Mln
EBITDA
$-60.02 Mln
Net Profit
$-60.63 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Gain Therapeutics (GANX)
| -43.6 | 3.7 | 1.4 | -5.5 | -18.5 | -25.2 | -- |
|
BSE Sensex
| -9.6 | -2.7 | 2.9 | -5.0 | 5.4 | 5.7 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Gain Therapeutics (GANX)
| 49.1 | -33.6 | 4.3 | -42.4 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Gain Therapeutics (GANX)
|
1.8 | 77.3 | 0.0 | -20.1 | -- | -134.7 | -- | 7.2 |
| 84.8 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 72.4 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 59.0 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 110.2 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 355.5 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 118.2 | 9,718.7 | 105.0 | -299.7 | -227.2 | -19.4 | -- | 6.6 | |
| 541.4 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 592.0 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 124.0 | 9,808.7 | 0.0 | -450.1 | -- | -44.6 | -- | 8.4 |
Shareholding Pattern
View DetailsAbout Gain Therapeutics (GANX)
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan... discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. Its lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson's disease with or without a GBA1 mutation. The company has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of dementia with Lewy bodies, Alzheimer's disease, and Gaucher's disease, lysosomal storage disorders, metabolic disorders, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is based in Bethesda, Maryland. Read more
-
Founder & Chairman
Dr. Khalid Islam Ph.D.
-
Founder & Chairman
Dr. Khalid Islam Ph.D.
-
Headquarters
Bethesda, MD
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Gain Therapeutics (GANX)
What is the current share price of Gain Therapeutics Inc (GANX) Today?
The share price of Gain Therapeutics Inc (GANX) is $1.82 (NASDAQ) as of 04-Sep-2026 13:32 EDT. Gain Therapeutics Inc (GANX) has given a return of -18.48% in the last 3 years.
What is the current PB & PE ratio of Gain Therapeutics Inc (GANX)?
Since, TTM earnings of Gain Therapeutics Inc (GANX) is negative, P/E ratio is not available.
The P/B ratio of Gain Therapeutics Inc (GANX) is 7.19 times as on 28-Aug-2026, a 39 premium to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-5.27 |
5.72 |
2024 |
-2.87 |
7.98 |
2023 |
-2.38 |
4.21 |
2022 |
-2.11 |
1.97 |
2021 |
-3.97 |
1.59 |
What is the 52 Week High and Low of Gain Therapeutics Inc (GANX)?
The 52-week high and low of Gain Therapeutics Inc (GANX) are Rs 4.34 and Rs 1.53 as of 05-Sep-2026.
What is the market cap of Gain Therapeutics Inc (GANX)?
Gain Therapeutics Inc (GANX) has a market capitalisation of $ 77 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Gain Therapeutics Inc (GANX)?
Before investing in Gain Therapeutics Inc (GANX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.